Acumen Pharmaceuticals, Inc.
NASDAQ:ABOSBiotechnology
+$0.02 today
- Market cap
- $165.63M
- Beta
- 0.35
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$1.79
Volume 0.81M
Average 0.40M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Acumen Pharmaceuticals, Inc.
NASDAQ:ABOS
Intrinsic Alpha fair value
Locked
Current Price
$2.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Opus Genetics, Inc. NASDAQ:IRD | $319.47M | $3.84 | Not rated | -33.0 | +111.40% |
Agenus Inc. NASDAQ:AGEN | $272.78M | $6.04 | Not rated | 1.7 | +43.12% |
Fate Therapeutics, Inc. NASDAQ:FATE | $208.64M | $1.79 | Not rated | -1.8 | +1.00% |
Alector, Inc. NASDAQ:ALEC | $205.45M | $1.84 | Not rated | -1.4 | +91.67% |
Seer, Inc. NASDAQ:SEER | $112.41M | $2.03 | Not rated | -1.4 | -28.61% |
Inovio Pharmaceuticals, Inc. NASDAQ:INO | $68.41M | $0.99 | Not rated | -8.9 | -1.16% |
Spero Therapeutics, Inc. NASDAQ:SPRO | $64.06M | $1.10 | Undervalued | 8.2 | -61.33% |
Seres Therapeutics, Inc. NASDAQ:MCRB | $24.46M | $2.46 | Overvalued | -1.3 | -75.67% |
Actuate Therapeutics Inc NASDAQ:ACTU | $14.53M | $0.61 | Not rated | -2.3 | -65.68% |
Continue the stock analysis
Jump to another research area for this company.